Akribion Genomics develops gene-editing tools and cancer therapies using CRISPR nuclease technology.
Akribion Genomics has raised $8.3M in total funding. The most recent round was Seed. The last funding was announced in February 2025.
Akribion Genomics's investors include HTGF (High-Tech Gruenderfonds), Carma Fund, RV Invest, Hessen Kapital I, Bruker Invest.
Akribion Genomics is headquartered in Zwingenberg, Germany.
Akribion Genomics develops gene-editing tools and cancer therapies using CRISPR nuclease technology.
Akribion Genomics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Akribion Genomics — Funding & Investors." VCBacked, February 4, 2025, https://www.vcbacked.co/company/akribion-genomics. Accessed August 1, 2026.
VCBacked. (2025). Akribion Genomics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/akribion-genomics
{{cite web |title=Akribion Genomics — Funding & Investors |url=https://www.vcbacked.co/company/akribion-genomics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated